Skip to content

Effect of transcutaneous electrical acupoint stimulation on analgesia, hemodynamics and plasma inflammatory factors during percutaneous nephrolithotomy: a randomized controlled trial

Effect of transcutaneous electrical acupoint stimulation on analgesia, hemodynamics and plasma inflammatory factors during percutaneous nephrolithotomy: a randomized controlled trial

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1800018254
Enrollment
Unknown
Registered
2018-09-07
Start date
2018-09-10
Completion date
Unknown
Last updated
2018-09-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

analgesia, hemodynamics and plasma inflammatory factors

Interventions

Sponsors

Tangshan people's Hospital Affiliated to North China University of science and technology
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: (1) patients who provided consent; (2) patients aged more than 18 years old; (3) patients with an American Society of Anesthesiology (ASA) physical status classification grade of I or II; and (4) patients with sufficient cognitive function and language skills for the study.

Exclusion criteria

Exclusion criteria: (1) patients with a painful condition (e.g. chronic migraine, rheumatoid arthritis, cancer pain etc.); (2) patients with a major organ system disease or hypersensitivity to the study medications; (3) patients fitted with a pacemaker; (4) participants using an analgesic drug or had a history of significant abuse of certain drugs; (5) Patients have received acupuncture point stimulation or had experience with acupuncture electrodes; (6) patients in whom the target acupoint stimulation site was infected, had trauma, or TEAS implementation was not appropriate to carry out for other reasons; (7) patients who had uncontrolled hypertension, diabetes, history of epilepsy, were pregnant, lactating or had childbearing potential, or were enrolled in other clinical trials.

Design outcomes

Primary

MeasureTime frame
VAS;ramsay score;MAP;HR;

Secondary

MeasureTime frame
Lidocaine dosage during operation;Adverse reaction rate;plasma level of TNF-a;plasma level of IL-6;plasma level of IL-8;plasma level of IL-10;

Countries

China

Contacts

Public ContactJianhui GAN

Tangshan people's Hospital Affiliated to North China University of science and technology

ganjianhui666@163.com+86 13363201508

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026